[go: up one dir, main page]

EP2683723B1 - Dérivés spirocycliques d'isoxazoline en tant qu'agents antiparasitaires - Google Patents

Dérivés spirocycliques d'isoxazoline en tant qu'agents antiparasitaires Download PDF

Info

Publication number
EP2683723B1
EP2683723B1 EP12709376.3A EP12709376A EP2683723B1 EP 2683723 B1 EP2683723 B1 EP 2683723B1 EP 12709376 A EP12709376 A EP 12709376A EP 2683723 B1 EP2683723 B1 EP 2683723B1
Authority
EP
European Patent Office
Prior art keywords
trifluoromethyl
azetidine
spiro
isobenzofuran
dihydroisoxazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP12709376.3A
Other languages
German (de)
English (en)
Other versions
EP2683723A1 (fr
Inventor
Denis Billen
Nathan Anthony Logan Chubb
Michael Curtis
Sean DW GREENWOOD
Sanjay Menon
Timothy Stuk
Valerie A. Vaillancourt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis Services LLC
Original Assignee
Zoetis Services LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services LLC filed Critical Zoetis Services LLC
Priority to HRP20160601TT priority Critical patent/HRP20160601T1/hr
Priority to MEP-2016-125A priority patent/ME02412B/fr
Priority to PL12709376T priority patent/PL2683723T3/pl
Priority to RS20160432A priority patent/RS54860B1/sr
Priority to SI201230583A priority patent/SI2683723T1/sl
Publication of EP2683723A1 publication Critical patent/EP2683723A1/fr
Application granted granted Critical
Publication of EP2683723B1 publication Critical patent/EP2683723B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N53/00—Biocides, pest repellants or attractants, or plant growth regulators containing cyclopropane carboxylic acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Definitions

  • This invention relates to spirocyclic isoxazoline derivatives having parasiticidal activity.
  • the compounds of interest are spirocyclic isoxazoline derivatives with an azetidine moiety.
  • the invention also relates to processes of making said spirocyclic isoxazoline derivatives, compositions and uses thereof.
  • antiparasitic agents for use with animals, and in particular there is a need for improved insecticides and acaricides. Furthermore there is a need for improved topical and oral products with convenient administration and which contain one or more of such antiparasitic agents which can be used to effectively treat ectoparasites, such as insects (e.g., fleas, lice, and flies) and acarids (e.g., mites and ticks).
  • insects e.g., fleas, lice, and flies
  • acarids e.g., mites and ticks
  • Such products would be particularly useful for the treatment of animals including: birds (e.g., chickens and turkeys), fish, companion animals (e.g., cats, dogs, llamas, and horses), and livestock (e.g., cattle, bison, swine, sheep, deer, elk, and goats).
  • birds e.g., chickens and turkeys
  • companion animals e.g., cats, dogs, llamas, and horses
  • livestock e.g., cattle, bison, swine, sheep, deer, elk, and goats.
  • Isoxazoline derivatives have been disclosed in the art as having insecticidal and acaricidal activity.
  • WO2007/105814 , WO2008/122375 , and WO2009/035004 recite certain alkylene linked amides.
  • WO2010/032437 discloses that the benzyl amide can be moved to the position ortho to the isoxazoline.
  • WO2007/075459 discloses phenyl isoxazolines substituted with 5- to 6-membered heterocycles
  • WO2010/084067 and WO2010/025998 disclose phenyl isoxazolines substituted with 10- to 11-membered fused aryl and heteroaryls.
  • the present invention overcomes one or more of the various disadvantages of, or improves upon, the properties of existing compounds.
  • the present invention develops new spirocyclic isoxazoline substituted azetidine compounds which demonstrate such properties.
  • the present invention provides Formula (1) compounds, stereoisomers thereof, and veterinarily acceptable salts thereof, which act as parasiticides, in particular, ectoparasiticides; therefore may be used to prevent, treat, repel, and control acarids and insect infection and infestation in animals.
  • the invention contemplates the control and prevention of tick borne diseases, for example, Lyme disease, canine and bovine anaplasmosis, canine ehrlichiosis, canine rickettsiosis, canine and bovine babesiosis, epizootic bovine abortion, and theileriosis.
  • tick borne diseases for example, Lyme disease, canine and bovine anaplasmosis, canine ehrlichiosis, canine rickettsiosis, canine and bovine babesiosis, epizootic bovine abortion, and theileriosis.
  • each of R 1a , R 1b , and R 1c are independently selected from hydrogen, fluoro, chloro, bromo, and C 1 -C 6 haloalkyl. In yet another aspect of the invention, each of R 1a , R 1b , and R 1c independently selected from hydrogen, fluoro, chloro, bromo, and -CF 3 . In another aspect of the invention, R 1a and R 1c are both chloro and R 1b is fluoro.
  • R 3 is -CF 3 , -CHF 2 , -CH 2 F, and -CF 2 Cl. In yet another aspect of the invention, R 3 is -CF 3 , -CHF 2 , and -CH 2 F. In yet another aspect of the invention, R 3 is -CF 3 .
  • R 5 is C 1 -C 6 alkyl.
  • R 5 is methyl, ethyl, propyl, isopropyl, t-butyl, and isobutyl.
  • Each of the R 5 C 1 -C 6 alkyls can be optionally substituted as defined herein, for example, with at least one substituent selected from hydroxyl, halo, trifluoromethyl, thiomethyl, thiotrifluoromethyl, -SO 2 CH 3 , -SO 2 CF 3 , and -NHCHO.
  • R 5 is C 0 -C 6 alkylC 3 -C 6 Cycloalkyl.
  • R 5 is cyclopropyl, cyclobutyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, and cyclopentyl.
  • Each of the R 5 C 0 -C 6 alkylC 3 -C 6 cycloalkyls can be optionally substituted as defined herein, for example, with at least one substituent selected from hydroxyl, -CH 2 OH, halo, methyl, ethyl, and trifluoromethyl.
  • R 5 is C 0 -C 6 alkylheteroaryl.
  • R 5 is -CH 2 pyrazole, and -CH 2 pyridazine.
  • Each of the R 5 C 0 -C 6 alkylheteroaryl moieties can be optionally substituted as defined herein, for example, with at least one substituent selected from hydroxyl, methyl, halo, and trifluoromethyl.
  • R 5 is C 0 -C 6 alkylheterocycle.
  • R 5 is oxetane, thiatane, azetidine, tetrahydrofuran, tetrahydrothiophene, and pyrrolidine.
  • Each of the R 5 C 0 -C 6 alkylheterocycle moieties can be optionally substituted as defined herein, for example, with at least one substituent selected from halo, -CH 2 OH, methyl, oxo, and trifluoromethyl.
  • R 5 C 1 -C 6 alkyl or C 0 -C 6 alkylC 3 -C 6 cycloalkyl moiety can be optionally and independently substituted by at least one substituent selected from halo, hydroxyl, hydroxyC 1 -C 6 alkyl-, C 1 -C 6 haloalkyl, or -S(O) p R c ; and wherein R 5 C 0 -C 6 alkylheteroaryl or C 0 -C 6 alkylheterocycle moiety can be further optionally substituted with at least one substituent selected from oxo, hydroxyl, hydroxyC 1 -C 6 alkyl-, C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl; R c is C 1 -C 6 alkyl; n is the integer 0; and
  • p is the integer 0, 1, or 2; stereoisomers thereof, and veterinarily acceptable salts thereof.
  • R 1a , R 1b , and R 1c are each independently hydrogen, chloro, fluoro, bromo, or trifluoromethyl;
  • R 5 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, cyclopropyl, or cyclobutyl, wherein each substituent can be optionally and independently substituted by at least one substituent selected from halo, hydroxyl, C 1 -C 6 haloalkyl, or -S(O) p R c ; or
  • R 5 is thietanyl, pyrazolyl, or -CH 2 pyrazolyl, wherein each substituent can be further optionally substituted with at least one substituent selected from oxo, or C 1 -C 6 alkyl; and
  • R c is methyl or e
  • a process for preparing the chiral spiroisoxazolines of Formula (63) of Scheme 6, comprising, optionally in a solvent, wherein the iodobromobenzyl derivative is 4-bromo-2-(chloromethyl)-1-iodobenzene and the protected azetidinone is 3-oxooazetidine-1-carboxylic acid tert-butyl ester or 1-benzhydrylazetidin-3-one.
  • a veterinary composition that comprises a) a Formula (1) compound, stereoisomers thereof, or a veterinarily acceptable salt thereof, and (b) a veterinarily acceptable excipient, diluent, or carrier.
  • the composition comprises a therapeutically effective amount of a Formula (1) compound, stereoisomer thereof, or veterinarily acceptable salt thereof, and a veterinarily acceptable excipient, diluent, or carrier.
  • composition may comprise at least one additional veterinary agent.
  • additional veterinary agents include endoparasiticides, endectocides, ectoparasiticides, insecticides, and anthelmintics, and are described herein.
  • the composition may comprise at least one additional veterinary agent.
  • additional veterinary agents include endoparasiticides, endectocides, ectoparasiticides, insecticides, and anthelmintics, and are described herein.
  • the additional veterinary agent is selected from amitraz, amino acetonitriles, anthelmintics (e.g., albendazole, cambendazole, fenbendazole, flubendazole, mebendazole, octadepsipeptides, oxfendazole, oxibendazole, paraherquamide, parbendazole, piperazines, praziquantel, thiabendazole, tetramisole, triclabendazole, levamisole, pyrantel pamoate, oxantel, morantel, and the like), avermectins (e.g., abamectin, dorame
  • amitraz
  • the additional agent is selected from an amino acetonitrile, albendazole, cambendazole, fenbendazole, flubendazole, mebendazole, oxfendazole, oxibendazole, paraherquamide, parbendazole, praziquantel, thiabendazole, tetramisole, triclabendazole, levamisole, pyrantel pamoate, oxantel, morantel, abamectin, doramectin, emamectin, eprinomectin, ivermectin, moxidectin, selamectin, milbemycin, milbemycin oxime, demiditraz, diethylcarbamazine, fipronil, hydroprene, kinoprene, methoprene, metaflumizone, niclosamide, pyriproxyfen, and spinos
  • the additional agent is selected from an amino acetonitrile, paraherquamide, praziquantel, abamectin, doramectin, emamectin, eprinomectin, ivermectin, moxidectin, selamectin, milbemycin, and milbemycin oxime.
  • the additional agent is selected from abamectin, doramectin, emamectin, eprinomectin, ivermectin, moxidectin, selamectin, milbemycin, and milbemycin oxime.
  • the additional agent is selected from abamectin, doramectin, eprinomectin, ivermectin, moxidectin, selamectin, milbemycin, and milbemycin oxime. In yet another aspect of the invention, the additional agent is selected from moxidectin, selamectin, and milbemycin oxime. In yet another aspect of the invention, the additional agent is selected from moxidectin and milbemycin oxime.
  • Compounds of Formula (1) may be used for the manufacture of a medicament.
  • the compound of Formula (1) of the invention is provided for use in the treatment of a parasitic infection or infestation in an animal.
  • Such treatment includes the step of administering to said animal, in need of such treatment, a therapeutically effective amount of a compound of the present invention, stereoisomer thereof, or veterinarily acceptable salt thereof.
  • the animal may be a mammal, and in one specific aspect of the invention the animal is a companion animal (for example, dog, cat, or horse).
  • the animal may also be livestock (for example, sheep, goat, cattle, and pig or the animal is a bird, specifically, fowl (for example, chicken, turkey, duck, and geese) or the animal is a fish.
  • the compounds of the present invention, and compositions thereof can be administered to the animal orally or topically.
  • the compounds of the present invention, and compositions thereof can also be administered to the animal by intramuscular-, intraperitoneal-, or subcutaneous-injection.
  • the compounds of the present invention, and compositions thereof can be administered to the animal orally or topically.
  • the use of the compounds of Formula (1) in the treatment of a parasitic infection or infestation in an animal that includes the step of administering to said animal, in need of such treatment, a therapeutically effective amount of a compound of the present invention, stereoisomer thereof, or veterinarily acceptable salt thereof, in combination with at least one additional veterinary agent.
  • the animal is a mammal, which in one aspect of the invention is specifically a companion animal (for example, dog, cat, or horse).
  • the animal may be livestock (for example, sheep, goat, cattle, and pig)or a bird, specifically, fowl (for example, chicken, turkey, duck, and geese) or a fish.
  • the compounds of the present invention, and compositions thereof can be administered to the animal orally or topically.
  • the compounds of the present invention, and compositions thereof can also be administered to the animal by intramuscular-, intraperitoneal-, or subcutaneous-injection.
  • the compounds of the present invention, and compositions thereof can be administered to the animal orally or topically.
  • the compounds of the present invention can be administered by injection.
  • Compounds of the present invention alone, or in combination with an additional veterinary agent(s) may be administered as (a) a single veterinary composition which comprises a compound of the present invention, stereoisomer thereof, veterinarily acceptable salt thereof, and optionally, at least one additional veterinary agent as described herein and a veterinarily acceptable excipient, diluent, or carrier; or (b) two separate veterinary compositions comprising (i) a first composition comprising a compound of the present invention, stereoisomer thereof, veterinarily acceptable salt thereof, and a veterinarily acceptable excipient, diluent, or carrier, and (ii) a second composition comprising at least one additional veterinary agent, as described herein and a veterinarily acceptable excipient, diluent, or carrier.
  • the veterinary compositions may be administered simultaneously or sequentially and in any order.
  • Alkyl refers to saturated monovalent hydrocarbon alkane radicals of the general formula C n H 2n+1 .
  • the alkane radical may be straight or branched and may be unsubstituted or substituted.
  • (C 1 -C 6 )alkyl refers to a monovalent, straight or branched aliphatic group containing 1 to 6 carbon atoms.
  • Non-exclusive examples of (C 1 -C 6 ) alkyl groups include, but are not limited to methyl, ethyl, propyl, isopropyl, sec-butyl, t-butyl, n-propyl, n-butyl, i-butyl, s-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, neopentyl, 3,3-dimethylpropyl, 2-methylpentyl, hexyl, and the like.
  • the alkyl moiety may be attached to the chemical moiety by any one of the carbon atoms of the aliphatic chain. Alkyl groups are optionally substituted as described herein.
  • alkylphenyl when used in compound words such as alkylphenyl, said alkyl moiety has the same meaning as herein defined and may be attached to the chemical moiety by any one of the carbon atoms of the aliphatic chain.
  • alkylphenyl include: C 1 alkylphenyl is -CH 2 phenyl, C 2 alkylphenyl is -CH 2 CH 2 phenyl, Cophenyl is phenyl, and the like.
  • Animal(s) refers to an individual animal that is a mammal, bird, or fish. Specifically, mammal refers to a vertebrate animal that is human and non-human, which are members of the taxonomic class Mammalia.
  • Non-exclusive examples of non-human mammals include companion animals and livestock.
  • Non-exclusive examples of a companion animal include: dog, cat, llama, and horse.
  • Preferred companion animals are dog, cat, and horse. More preferred is dog.
  • Non-exclusive examples of livestock include: swine, camel, rabbits, goat, sheep, deer, elk, bovine (cattle), and bison.
  • Preferred livestock is cattle and swine.
  • bird refers to a vertebrate animal of the taxonomic class Aves. Birds are feathered, winged, bipedal, endothermic, and egg-laying.
  • Non-exclusive examples of bird include, poultry (e.g., chicken, turkey, duck, and geese), all of which are also referred to herein as fowl.
  • fish refers to the taxonomic class Chondrichthyes (cartilaginous fishes, e.g., sharks and rays) and Osteichthyes (bony fishes) which live in water, have gills or mucus-covered skin for respiration, fins, and may have scales.
  • Non-exclusive examples of fish include shark, salmon, trout, whitefish, catfish, tilapia, sea bass, tuna, halibut, turbot, flounder, sole, striped bass, eel, yellowtail, grouper, and the like.
  • Carbocyclic refers to a partially saturated or saturated 5- to 7-membered ring containing only carbon atoms and can be monocyclic or part of a fused ring or spiro ring moiety.
  • Examples of carbocyclic rings include cyclopentane, cyclohexane, and cycloheptane. The carbocyclic ring is optionally substituted as described herein.
  • Chiral refers to the structural characteristic of a molecule that makes it impossible to superimpose it on its mirror image, (e.g., "R” and “S” enantiomers).
  • the term is also depicted as an asterisk (i.e.,*) in the Eamples and preparations and refers to a chiral center which includes both the S and R enantiomers.
  • Cycloalkyl includes fully saturated or partially saturated carbocyclic alkyl moieties.
  • partially saturated cycloalkyls include: cyclopropene, cyclobutene, cycloheptene, cyclooctene, cyclohepta-1,3-diene, and the like.
  • Preferred cycloalkyls are 3- to 6-membered saturated monocyclic rings including cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • the cycloalkyl group may be attached to the chemical moiety by any one of the carbon atoms within the carbocyclic ring.
  • Cycloalkyl groups are optionally substituted with at least one substituent. Further when used in compound words such as alkylcycloalkyl, said alkyl and cycloalkyl moiety has the same meaning as herein defined and may be attached to the chemical moiety by any one of the carbon atoms of the aliphatic chain.
  • C 0 -C 6 alkylC 3 -C 6 cycloalkyl examples include, methylcyclopropane (C 1 alkylC 3 cycloalkyl or -CH 2 cyclopropane), ethylcyclopropane (C 2 alkylC 3 cycloalkyl or -CH 2 CH 2 cyclopropane), methylcyclobutane (C 1 alkylC 4 cycloalkyl or -CH 2 cyclobutane), ethylcyclobutane (C 2 alkylC 4 cycloalkyl or -CH 2 CH 2 cyclobutane), methylcyclohexane (C 1 alkylC 6 cycloalkyl or -CH 2 cyclohexane), and the like.
  • C 0 alkylC 3 -C 6 cycloalkyl is C 3 -C 6 cycloalkyl. Cycloalkyl moieties are optionally substituted as
  • Halogen or "halo”, as used herein, unless otherwise indicated, refers to fluorine, chlorine, bromine and iodine. Further, when used in compound words such as “haloalkyl” or “haloalkoxy”, said alkyl or alkoxy may be partially or fully substituted with halogen atoms which may be the same or different and said alkyl or alkoxy moiety has the same meaning as above and may be attached to the chemical moiety by any one of the carbon atoms of the aliphatic chain. Examples of “haloalkyl” include F 3 C-, ClCH 2 -, CF 3 CH 2 - and CF 3 CCl 2 -, and the like.
  • haloalkoxy is defined analogously to the term “haloalkyl”.
  • haloalkoxy include CF 3 O-, CCl 3 CH 2 O-, HCF 2 CH 2 CH 2 O- and CF 3 CH 2 O-, and the like.
  • Heteroaryl or “Het”, as used herein, unless otherwise indicated, refers to a 5- to 6-membered aromatic monocyclic ring or an 8- to 10-membered fused aromatic ring where said monocyclic- and fused-ring moiety contains one or more heteroatoms each independently selected from N, O, or S, preferably from one to four heteroatoms.
  • Non-exclusive examples of monocyclic heteroaryls include pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, thiazolyl, isoxazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, and the like.
  • fused heteroaryls include: benzofuranyl, benzothiophenyl, indolyl, benzimidazolyl, indazolyl, benzotriazolyl, thieno[2,3-c]pyridine, thieno[3,2-b]pyridine, benzo[1,2,5]thiadiazole, and the like.
  • the heteroaryl group may be attached to the chemical moiety by any one of the carbon atoms or nitrogen heteroatoms within the monocyclic or fused ring.
  • alkyl and heteroaryl moiety have the same meaning as herein defined and may be attached to the chemical moiety by any one of the carbon atoms of the aliphatic chain.
  • C 0 alkylheteroaryl is heteroaryl
  • C 1 alkylheteroaryl is -CH 2 heteroaryl
  • C 2 alkylheteroaryl is -CH 2 CH 2 heteroaryl
  • Heteroaryls are optionally substituted as described herein.
  • Heterocycle refers to a partially saturated or saturated 3- to 7-membered monocyclic ring containing one or more heteroatoms each independently selected from N, O, or S, preferably from one to four heteroatoms.
  • the heterocyclic ring can be part of a fused ring or spiro-ring moiety.
  • heterocycle examples include oxirane, thiarane, aziridine, oxetane, azetidine, thiatane, tetrahydrofuran, tetrahydrothiophene, pyrrolidine, tetrahydropyrane, piperidine, piperazine, tetrahydropyridine, 2H-azirine, 2,3-dihydro-azete, 3,4-dihydro-2H-pyrrole, and the like.
  • the heterocycle group may be attached to the chemical moiety by any one of the carbon atoms or nitrogen heteroatoms within the ring.
  • alkyl and heterocycle moiety have the same meaning as herein defined and may be attached to the chemical moiety by any one of the carbon atoms of the aliphatic chain.
  • C 0 alkylheterocycle is heterocycle
  • C 1 alkylheterocycle is -CH 2 heterocycle
  • C 2 alkylheterocycle is -CH 2 CH 2 heterocycle, and the like.
  • Heterocycles are optionally substituted as described herein.
  • Optionally substituted is used herein interchangeably with the phrase substituted or unsubstituted. Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position of the group, and each substitution is independent of the other. An optionally substituted group also may have no substituents. Therefore, the phrase "optionally substituted with at least one substituent” means that the number of substituents may vary from zero up to a number of available positions for substitution.
  • Parasite(s) refers to endoparasites and ectoparasites.
  • Endoparasites are parasites that live within the body of its host and include helminths (e.g., trematodes, cestodes, and nematodes) and protozoa.
  • Ectoparasites are organisms of the Arthropoda phylum (e.g., arachnids, insects, and crustaceans (e.g., copepods-sea lice) which feed through or upon the skin of its host.
  • Preferred arachnids are of the order Acarina, e.g., ticks and mites.
  • Preferred insects are midges, fleas, mosquitos, biting flies (stable fly, horn fly, blow fly, horse fly, and the like), bed bugs, and lice.
  • Preferred compounds of the present invention can be used for the treatment of parasites, i.e., treatment of a parasitic infection or infestation.
  • Protecting group refers to a substituent that is commonly employed to block or protect an amine on the compound thereby protecting its functionality while allowing for the reaction of other functional groups on the compound.
  • Non-exclusive examples of an amine-protecting group include: acyl groups (e.g., formyl, acetyl, chloroacetyl, trichloroacetyl, O -nitrophenylacetyl, O -nitrophenoxyacetyl, trifluoroacetyl, acetoacetyl, 4-chlorobutyryl, isobutyryl, O -nitrocinnamoyl, picolinoyl, acylisothiocyanate, aminocaproyl, benzoyl, and the like), acyloxy groups (e.g., 1- tert -butyloxycarbonyl (Boc), methoxycarbonyl, 9-fluorenyl-methoxycarbony
  • Sulfonate leaving group refers to anions with the general formula RSO 2 O-.
  • “Therapeutically effective amount” refers to an amount of the compounds of the present invention that (i) treat the particular parasitic infection or infestation, (ii) attenuates, ameliorates, or eliminates one or more symptoms of the particular parasitic infection or infestation, or (iii) prevents or delays the onset of one or more symptoms of the particular parasitic infection or infestation described herein.
  • Treatment refers to reversing, alleviating, or inhibiting the parasitic infection, infestation, or condition.
  • these terms also encompass, depending on the condition of the animal, preventing the onset of a disorder or condition, or of symptoms associated with a disorder or condition, including reducing the severity of a disorder or condition or symptoms associated therewith prior to affliction with said infection or infestation.
  • treatment can refer to administration of the compounds of the present invention to an animal that is not at the time of administration afflicted with the infection or infestation. Treating also encompasses preventing the recurrence of an infection or infestation or of symptoms associated therewith as well as references to "control” (e.g., kill, repel, expel, incapacitate, deter, eliminate, alleviate, minimize, and eradicate).
  • Veterinary acceptable indicates that the substance or composition must be compatible chemically and/or toxicologically, with the other ingredients comprising a formulation, composition, and/or the animal being treated therewith.
  • pharmaceutically acceptable has the same meaning as that recited for “veterinarily” acceptable.
  • the present invention provides Formula (1) compounds, stereoisomers thereof, as well as veterinary compositions that are useful as antiparasitic agents for animals, in particular, compounds that act as ectoparasiticides.
  • Compounds of the present invention may be synthesized by synthetic routes that include processes analogous to those well known in the chemical arts, particularly in light of the description contained herein.
  • the starting materials are generally available from commercial sources such as Aldrich Chemicals (Milwaukee, Wis.) or are readily prepared using methods well known to those skilled in the art (e.g., prepared by methods generally described in Louis F. Fieser and Mary Fieser, "Reagents for Organic Synthesis", 1; 19, Wiley, New York (1967, 1999 ed .), or Beilsteins Handbuch der organischen Chemie, 4, Aufl. ed. Springer-Verlag, Berl in, including supplements (also available via the Beilstein online database)).
  • reaction schemes depicted below demonstrate potential routes for synthesizing compounds of the present invention, and key intermediates.
  • Examples section below A skilled artisan will appreciate that other suitable starting materials, reagents, and synthetic routes may be used to synthesize the compounds of the present invention and a variety of derivatives thereof.
  • many of the compounds prepared by the methods described below can be further modified in light of this disclosure using conventional chemistry well known to the skilled artisan.
  • Enantiomeric mixtures can be separated into their individual enantiomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as chromatography and/or fractional crystallization.
  • chromatography and/or fractional crystallization A more detailed description of techniques that can be used to resolve stereoisomers of compounds from their racemic mixture can be found in Jean Jacques Andre Collet, Samuel H. Wilen, Enantiomers, Racemates and Resolutions, John Wiley and Sons, Inc. (1981 ).
  • Compounds of this invention can exist as one or more stereoisomers.
  • the various stereoisomers include enantiomers, diastereomers and atropisomers.
  • one stereoisomer may be more active and/or may exhibit beneficial effects when enriched relative to the other stereoisomer(s) or when separated from the other stereoisomer(s). Additionally, the skilled artisan knows how to separate, enrich, and/or to selectively prepare said stereoisomers.
  • the compounds of the invention may be present as a mixture of stereoisomers, individual stereo isomers or as an optically active form.
  • Formula 1 a two possible enantiomers of Formula 1 are depicted as Formula 1 a and Formula Ib involving the spirocyclic isoxazoline chiral center identified with an asterisk (*).
  • Molecular depictions drawn herein follow standard conventions for depicting stereochemistry.
  • the substituents, R 1a , R 1b , R 1c , R 2 , R 3 , R 4 , W, X, and n are as defined herein.
  • protecting group refers to a substituent that is commonly employed to block or protect a particular functionality while reacting other functional groups on the compound.
  • an amine-protecting group is a substituent attached to an amine that blocks or protects the amine-functionality of the compound or intermediate.
  • Suitable amine protecting groups include: 1- tert -butyloxycarbonyl (Boc), acyl groups including: formyl, acetyl, chloroacetyl, trichloro-acetyl, o-nitrophenylacetyl, o-nitrophenoxyacetyl, trifluoroacetyl, acetoacetyl, 4-chlorobutyryl, isobutyryl, o- nitrocinnamoyl, picolinoyl, acylisothiocyanate, aminocaproyl, benzoyl, and the like; and acyloxy groups including: methoxycarbonyl, 9-fluorenyl-methoxycarbonyl, 2,2,2-trifluoroethoxycarbonyl, 2-trimethylsilylethxoycarbonyl, vinyloxycarbonyl, allyloxycarbonyl, 1,1-dimethyl-propynyloxycarbonyl, benzyloxy-carbonyl,
  • diphenylmethane and benzylcarbamates can be used as amine protecting groups.
  • Suitable protecting groups and their respective uses are readily determined by one skilled in the art. For a general description of protecting groups and their use, see T. W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, New York, 1991 .
  • catalysts/reactants and miscellaneous abbreviations include: mobile phase (MP); supercritical fluid chromatography (SFC); N,N-dimethyl formamide (DMF); dimethyl acetamide (DMA); acetonitrile (ACN or Acn); formic acid (FA); dichloromethane (DCM); N-chloro-succinimide (NCS); ethanol (EtOH); methyl tert-butyl ether (MTBE); triethylamine (TEA); methanol (MeOH), tetrahydrofuran (THF); ethyl acetate (EtOAc); trifluoroacetic acid (TFA); triphenylphosphine palladium (Pd(PPh 3 ) 4 ); (2,2,6,6-tetramethylpiperidin-1-yl)oxyl (TEMPO); and diisobutylaluminium hydride (DIBAL-H); 4-d
  • the aryl olefins ( 1AB ) can be prepared according to Scheme 1.
  • the requisite organoborates can be prepared as boronate ester intermediates (1 B2) from literature methods ( Org. Lett. 2007, 9, 761-764 ) or purchased as boronic acids (1A1) such as 3,5-dichloroboronic acid from Aldrich.
  • Intermediate 1A1 or 1 B2 compounds can be added to dioxane or THF and water, followed by 2-bromo-3,3,3-trifluoropropene, potassium carbonate, and bis (triphenylphosphine) palladium II chloride to afford the intermediate olefin ( 1AB ) compounds.
  • the iodoester 2 can be prepared by treatment of the aminoester 1 with sodium nitrite and potassium iodide. Reduction of the ester to the alcohol with diisobutylaluminum hydride followed by oxidation with TEMPO or Dess-Martin affords the iodoaldehyde 4. This aldehyde can undergo condensation with hydroxylamine, chlorination and cyclization to give the isoxazoline 6. Grignard formation using iPrMgCl occurs selectively with the iodine and the resulting organometallic adds to the N-protected azetidinone to afford the phenylazetidine 7. Lactone 8 can be prepared through metal-catalyzed cyanation followed by intramolecular cyclization upon aqueous work-up. R 1a , R 1b , R 1c , R 2 , and n are as defined herein.
  • Phenylazetidine 7 can undergo a metal-catalyzed intramolecular cyclization in the presence of carbon monoxide to afford lactone 21. Reduction of 21 using a reducing agent such as LiBH 4 provides bis-alcohol 22. Subsequent mesylation using methanesulfonyl chloride followed by displacement of the leaving group gives ether 23. Additionally, nitrogen or sulfur analogs of ether 23 can be made in a similar manner employing an amine derivative or thioacetate. Removal of the benzhydryl protecting group with chloroethyl-chloroformate provides the azetidine 24. R 1a , R 1b , R 1c , R 2 , R 5 , X, W, and n are as defined herein.
  • Amide analogs of the azetidine ring can be prepared as shown in Scheme 10. Acylation of the azetidine ring can be accomplished by reaction of the azetidine 43 with an acid chloride in pyridine/DMA or by a condensation with a carboxylic acid utilizing a condensing agent such as HATU or HOBt to afford the substituted azetidine 44.
  • R 1a , R 1b , R 1c , R 2 , R 5 , and n are as defined herein.
  • the single enantiomers of the compounds described herein can be obtained from chiral supercritical fluid chromatography (SFC) separation.
  • Chiral SFC separation of intermediate 53 provides a chiral intermediate which may be carried on to the single enantiomer of the described spiroazetidines.
  • chiral separation may be performed on the final racemic product to provide both enantiomers of 54 as discreet products.
  • Conditions for the chiral separation can be found in the examples section.
  • R 1a , R 1b , R 1c , R 2 , R 5 , and n are as defined herein.
  • the R 8 substituent depicts a C 1 -C 6 alkyl moiety (e.g., methyl, ethyl, propyl, isopropyl, butyl, and the like).
  • Pg is a protecting group, for example Boc, diphenylmethane, or a benzylcarbamate and Y 2 can be bromine, chlorine, iodine, hydroxyl, or a sulfonate leaving group.
  • the asterisk (*) depicts a chiral center, (i.e., R or S stereochemistry).
  • the present invention includes all veterinarily acceptable isotopically-labelled Formula (1) compounds wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes suitable for inclusion in the compounds of the present invention include isotopes of hydrogen, such as 2 H and 3 H, carbon, such as 11 C, 13 C and 14 C, chlorine, such as 36 Cl, fluorine, such as 18 F, iodine, such as 123 I and 125 I, nitrogen, such as 13 N and 15 N, oxygen, such as 15 O, 17 O and 18 O, and sulphur, such as 35 S.
  • the Formula (1) compounds are useful as antiparasitic agents, therefore, another embodiment of the present invention is a veterinary composition comprising a therapeutically effective amount of a Formula (1) compound, stereoisomer thereof, and a veterinarily acceptable excipient, diluent or carrier.
  • the compounds of the present invention (including the compositions and processes used therein) may also be used in treatment of a parasitic infection or infestation in an animal or in the manufacture of a medicament for the therapeutic applications described herein.
  • a typical formulation is prepared by mixing a Formula (1) compound with a carrier, diluent or excipient.
  • Suitable carriers, diluents and excipients are well known to those skilled in the art and include materials such as carbohydrates, waxes, water soluble and/or swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water, and the like.
  • the particular carrier, diluent or excipient used will depend upon the means and purpose for which the compound of the present invention is being applied. Solvents are generally selected based on solvents recognized by persons skilled in the art as safe to be administered to an animal.
  • the formulations may also include one or more buffers, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents and other known additives to provide an elegant presentation of the drug (i.e., a compound of the present invention or veterinary composition thereof) or aid in the manufacturing of the veterinary product (i.e., medicament).
  • buffers stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents and other known additives to provide an elegant presentation of the drug (i.e., a compound of the present invention or veterinary composition thereof) or aid in the manufacturing of the veterinary product (i.e.
  • the formulations can be prepared using conventional dissolution and mixing procedures. Such compositions and methods for their preparation may be found, for example, in 'Remington's Veterinary Sciences', 19th Edition (Mack Publishing Company, 1995 ; and " Veterinary Dosage Forms: Tablets, Vol. 1", by H. Lieberman and L. Lachman, Marcel Dekker, N.Y., 1980 (ISBN 0-8247-6918-X ).
  • the bulk drug substance i.e., compound of the present invention or stabilized form of the compound (e.g., complex with a cyclodextrin derivative or other known complexation agent)
  • the compounds of the present invention are typically formulated into veterinary dosage forms to provide an easily controllable dosage form for administration.
  • the compounds may be administered alone or in a formulation appropriate to the specific use envisaged, the particular species of host animal being treated and the parasite involved. Generally, they will be administered as a formulation in association with one or more veterinarily acceptable excipients, diluents, or carriers.
  • excipient means any ingredient other than the Formula (1) compounds or any additional antiparasitic agent.
  • excipient, diluent, or carrier will to a large extent depend on factors such as the particular mode of administration, the effect of the excipient, carrier, or diluent on solubility and stability, and the nature of the dosage form.
  • the compounds of the present invention may be administered by oral, topical, and subcutaneous administration.
  • the preferred administration of the Formula (1) compounds is in an oral solid dosage form or oral liquid dosage form.
  • the Formula (1) compounds can be administered orally by capsule, bolus, tablet, powders, lozenges, chews, multi and nanoparticulates, gels, solid solution, films, sprays, or liquid form. This is a preferred administration route and as such it is desirable to develop active Formula (1) compounds that are particularly suited to such formulations.
  • Such formulations may be employed as fillers in soft or hard capsules and typically comprise a carrier, for example, water, ethanol, polyethylene glycol, N-methylpyrrolidone, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents.
  • Liquid forms include suspensions, solutions, syrups, drenches and elixirs.
  • Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.
  • Oral drenches are commonly prepared by dissolving or suspending the active ingredient in a suitable medium.
  • Oral formulations can comprise from about 0.5 mg/kg to 50 mg/kg of a Formula (1) compound, and preferably about 1 mg/kg to 30 mg/kg of a Formula (1) compound.
  • the compounds may be administered topically to the skin or mucosa, that is dermally or transdermally. This is a preferred route of administration and as such it is desirable to develop active Formula (1) compounds that are particularly suited to such formulations, for example liquid forms.
  • Typical formulations for this purpose include pour-on, spot-on, multi-spot-on, stripe-on, comb-on, roll-on, dip, spray, mousse, shampoo, powder formulation, gels, hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibers, bandages and micro emulsions. Liposomes may also be used.
  • Typical carriers include alcohol, water, mineral oil, liquid petrolatum, white petrolatum, glycerin, N-methyl formamide, glycol monomethyl ethers, polyethylene glycol, propylene glycol, and the like.
  • Penetration enhancers may be incorporated - see, for example, J Pharm Sci, 88 (10), 955-958 by Finnin and Morgan (October 1999 ).
  • Pour-on or spot-on formulations may be prepared by dissolving the active ingredients in an acceptable liquid carrier vehicle such as butyl digol, liquid paraffin or a non-volatile ester, optionally with the addition of a volatile component such as propan-2-ol or a glycol ether.
  • Topical formulations of the combination contemplated herein can comprise from about 0.5 mg/kg to 50 mg/kg of a Formula (1) compound, and preferably about 1 mg/kg to 10 mg/kg of a Formula (1) compound.
  • the compounds of the present invention can also be administered topically via a support matrix for example, a synthetic or natural resin, plastic, cloth, leather, or other such polymeric system in the shape of a collar or ear tag.
  • Said collar or ear tag may be coated, impregnated, layered, by any means so as to provide a veterinarily acceptable amount of a compound of the present invention alone, or with a veterinarily acceptable excipient, diluent, or carrier, and optionally an additional veterinary agent, or veterinarily acceptable salt thereof.
  • compositions suitable for spot-on application according to the invention can be prepared by conventional mixing means.
  • the volume of the applied composition can be from about 0.5 mL/kg to 5 mL/kg and preferably from about 1 mL/kg to 3mL/kg.
  • Agents may be added to the formulations of the present invention to improve the persistence of such formulations on the surface of the animal to which they are applied, for example to improve their persistence on the coat of the animal. It is particularly preferred to include such agents in a formulation which is to be applied as a pour-on or spot-on formulation.
  • agents include acrylic copolymers and in particular fluorinated acrylic copolymers.
  • a particular suitable reagent is the trademark reagent "Foraperle” (Redline Products Inc, Texas, USA).
  • Certain topical formulations may include unpalatable additives to minimize oral exposure.
  • Subcutaneous injectable formulations may be prepared in the form of a sterile solution, which may contain other substances, for example enough salts or glucose to make the solution isotonic with blood.
  • Acceptable liquid carriers include vegetable oils such as sesame oil, glycerides such as triacetin, esters such as benzyl benzoate, isopropyl myristate and fatty acid derivatives of propylene glycol, as well as organic solvents such as pyrrolidin-2-one and glycerol formal.
  • the formulations are prepared by dissolving or suspending compounds of the instant invention alone or with an additional veterinary agent in the liquid carrier such that the final formulation contains from about 0.01 to 10% by weight of the active ingredients.
  • Suitable devices for subcutaneous administration include needle (including micro needle) injectors, needle-free injectors and infusion techniques.
  • Subcutaneous formulations are typically aqueous solutions which may contain excipients such as salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dry powder form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water.
  • a suitable vehicle such as sterile, pyrogen-free water.
  • the preparation of subcutaneous formulations under sterile conditions for example, by lyophilisation, may readily be accomplished using standard veterinary techniques well known to those skilled in the art.
  • the solubility of compounds of Formula (1) used in the preparation of subcutaneous solutions may be increased by the use of appropriate formulation techniques, such as the incorporation of solubility-enhancing agents.
  • Such formulations are prepared in a conventional manner in accordance with standard medicinal or veterinary practice. Further, these formulations will vary with regard to the weight of active compound contained therein, depending on the species of host animal to be treated, the severity and type of infection or infestation, and the body weight of the animal.
  • compounds of the present invention may be administered alone or in combination with at least one additional veterinary agent including insecticides, acaricides, anthelmintics, fungicides, nematocides, antiprotozoals, bactericides, and growth regulators to form a multi-component agent giving an even broader spectrum of veterinary utility.
  • the present invention also pertains to a composition comprising an effective amount of a Formula (1) compound, a stereoisomer thereof, and an effective amount of at least one additional veterinary agent and can further comprise one or more of a veterinarily acceptable excipient, diluent, or carrier.
  • additional veterinary agents include: amitraz, arylpyrazoles as recited in publications WO1998/24767 and WO2005/060749 , amino acetonitriles, anthelmintics (e.g., albendazole, cambendazole, fenbendazole, flubendazole, mebendazole, octadepsipeptides, oxfendazole, oxibendazole, paraherquamide, parbendazole, piperazines, praziquantel, thiabendazole, tetramisole, triclabendazole, levamisole, pyrantel pamoate, oxantel, morantel, and the like), avermectins (e.g., abamectin, doramec
  • compositions comprising a veterinarily acceptable excipient, diluent, or carrier, for example, for the purpose of treating a particular parasitic infection or infestation or condition associated therewith.
  • two or more veterinary compositions at least one of which contains a Formula (1) compound in accordance with the invention, and the other, an additional veterinary agent, may conveniently be combined in the form of a kit suitable for coadministration of the compositions.
  • the compounds of the present invention may also be used in the treatment of a parasitic infection or infestation in an animal, or the manufacture of a medicament for the therapeutic applications described herein.
  • the compounds of the present invention stereoisomers thereof, and compositions comprising a therapeutically effective amount of a Formula (1) compound and a veterinarily acceptable excipient, diluent, or carrier are useful as ectoparasiticides for the control and treatment of infections or infestations manifested by said ectoparasite in an animal.
  • the compounds of the present invention have utility as an ectoparasiticide, in particular, as an acaricide and insecticide.
  • They may, in particular, be used in the fields of veterinary medicine, livestock husbandry and the maintenance of public health: against acarids, insects, and copepods which are parasitic upon vertebrates, particularly warm-blooded vertebrates, including companion animals, livestock, and fowl and cold-blooded vertebrates like fish.
  • acaride, insect, and copepod parasites include: ticks (e.g., Ixodes spp., Rhipicephalus spp., Boophilus spp., Amblyomma spp., Hyalomma spp., Haemaphysalis spp., Dermacentor spp., Ornithodorus spp., and the like); mites (e.g., Dermanyssus spp., Sarcoptes spp., Psoroptes spp., Chorioptes spp., Demodex spp., and the like); chewing and sucking lice (e.g., Damalinia spp., Linognathus spp., and the like); copepods (e.g., sea lice within the Order Siphonostomatoida, including genera Lepeophtheirus and Caligus); fleas (e.g., Siphonapt
  • the compounds of the invention can also be used for the treatment of endoparasites, for example, heartworms, roundworms, hookworms, whipworms, and tapeworms.
  • the compounds of the present invention and compositions comprising compounds of the present invention in conjunction with at least one other veterinary agent are of particular value in the control of ectoparasites, endoparasites, and insects which are injurious to, or spread or act as vectors of diseases in companion animals, livestock, birds, and fish.
  • the ectoparasites, insects, and endoparasites which can be treated with a combination of a Formula (1) compound and an additional veterinary agent include those as herein before described and including helminthes of the phylum platyhelminthes (e.g., trematodes, eucestoda, and cestoda), and nemathelminthes (e.g., nematodes).
  • Any of the compounds of the present invention, or a suitable combination of a compound of the present invention and optionally, with at least one additional veterinary agent may be administered directly to the animal and/or indirectly by applying it to the local environment in which the animal dwells (such as bedding, enclosures, and the like).
  • Direct administration includes contacting the skin, fur, or feathers of a subject animal with the compound(s), or by feeding or injecting the compounds into the animal.
  • the Formula (1) compounds, stereoisomers thereof, and combinations with at least one additional veterinary agent, as described herein, are of value for the treatment and control of the various lifecycle stages of insects and parasites including egg, nymph, larvae, juvenile and adult stages.
  • Also disclosed is a method of administering a compound of the present invention alone or in combination with at least one additional veterinary agent, and optionally a veterinarily acceptable excipient, diluent, or carrier, to animals in good health comprising the application to said animal to reduce or eliminate the potential for human parasitic infection or infestation from parasities carried by the animal and to improve the environment in which the animals inhabit.
  • reaction flasks were fitted with rubber septa for the introduction of substrates and reagents via syringe.
  • Glassware was oven dried and/or heat dried.
  • Analytical thin layer chromatography (TLC) was performed using glass-backed silica gel 60 F 254 precoated plates and eluted with appropriate solvent ratios (v/v). Reactions were assayed by TLC or LCMS and terminated as judged by the consumption of starting material. Visualization of the TLC plates was done with UV light (254 nM wavelength) or with an appropriate TLC visualizing solvent and activated with heat.
  • Flash column chromatography ( Still et al., J. Org. Chem. 43, 2923, (1978 ) was performed using silica gel (RediSep Rf) or various MPLC systems, such as Biotage or ISCO purification system.
  • This compound was made from the compound of Preparation 4 according to the procedures of Preparations 5 and 6, utilizing 1,3-dichloro-2-fluoro-5-(1,1,1-trifluoroprop-2-en-2-yl)benzene in place of 1,2,3-trichloro-5-(1,1,1-trifluoroprop-2-en-2-yl)benzene.
  • m/z (CI) 695 [M+H] + .
  • a stream of carbon monoxide gas was bubbled through a solution of of 1-benzhydryl-3-(2-bromo-4-(5-(3,5-dichlorophenyl-4-fluoro)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)phenyl)azetidin-3-ol (Preparation 8, 50g, 72mmol) in toluene (100mL) and triethylamine (100mL) for 30 seconds. To this was added palladium acetate (260mg) and Xantphos (680mg, 1.2mmol). A balloon containing carbon monoxide was attached to the reaction flask and it was heated to 85°C for 4 hours.
  • Example 1 1-(5'-(5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azetidine-3,1'-isobenzofuran]-1-yl)-2-((trifluoromethyl)thio)ethanone
  • HPLC conditions Instrument: Waters Alliance 2795 with ZQ MS-ESI+; Column: 4.6 x 100 NXC18, 5 ⁇ m; Flow Rate: 1.0 mL/minute; solvent A 0.05% TFA in water; solvent B ACN; Gradient: 50 to 95 %B from 0 to 10 minutes; Injection Volume: 2 ⁇ l; Run time: 12 minutes; Detection: 254 nm, and appropriate mass.
  • Instrument Waters Alliance 2795 with ZQ MS-ESI+; Column: 4.6 x 100 NXC18, 5 ⁇ m; Flow Rate: 1.0 mL/minute; solvent A 0.05% TFA in water; solvent B ACN; Gradient: 50 to 95 %B from 0 to 10 minutes; Injection Volume: 2 ⁇ l; Run time: 12 minutes; Detection: 254 nm, and appropriate mass.
  • Butyl vinyl ether (190uL, 1.5mmol) was subsequently added and the reaction was heated to 90°C for 4 hours under nitrogen. The reaction was cooled and 1.0N HCl (2mL) was added at room temperature and stirred for 2 hours. The reaction was neutralized with saturated NaHCO 3 and extracted with EtOAc. The organic phase was dried (Na 2 SO4) and concentrated under vacuum. The crude material was chromatographed (12g Redi-Sep column) eluting from 100% hexanes to 35:65 EtOAc:hexanes to afford the intermediate (172mg, 77%) as a solid.
  • One neck was equipped with a modified short path Dean-Stark head with a condenser on top, and the other with a very low flow nitrogen input (the nitrogen input is off at the beginning of the reaction).
  • the reaction was heated to 110°C.
  • the starting material quickly dissolved and Cs 2 CO 3 (5g, 16 mmols) was then added.
  • a vigorous effervescence was observed and the nitrogen flow was connected.
  • the reaction was stirred for 1 hour, emptying the Dean-Stark trap as necessary.
  • HPLC-MS shows about 75% progress.
  • Another 1g of Cs 2 CO 3 was added to the crude mixture and the reaction was stirred for an additional 1 hour.
  • An HPLC-MS shows >95% conversion.
  • the crude reaction was then poured into 500mL TBME and filtered through a 2" cake of silica.
  • the solvents are removed under vacuum, and the resulting brown gum is re-dissolved in a 1:1 mix of TBME:hexanes, filtered over a 5" cake of silica, and eluted with 2L of the same solution.
  • the organics were concentrated to dryness.
  • the solids were dissolved in a 95:5 mix of hot heptane:TBME (c.a. 250ml).
  • the solution was then slowly cooled to 0°C with stirring and seeded with solids from previous batches. A beige solid formed after 30 minutes.
  • the slurry was left stirring at 0°C for 2 hours.
  • the solution was concentrated to a volume of 3mL and then 15mL of methyl tert -butyl ether was added and the heterogeneous mixture was stirred at ambient temperature for 15 minutes. The precipitated catalyst was removed by filtration. The organic solution at this point contained a 90:10 mixture of isoxazoline enantiomers. The organics were concentrated to a volume of 3mL and the product was allowed to slowly crystallize at ambient temperature and was then cooled to 0°C. The product was isolated by filtration to afford 910mg (89%) of white crystals. The crystallization generally provided an enatiomeric upgrading such that the percentage of active isomer was >95%.
  • Example 5 Chiral-1-(5'-(5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azetidine-3,1'-isobenzofuran]-1-yl)-2-(methylsulfinyl)ethanone - mixture of diastereomers at the sulfoxide
  • Example 6 Chiral -1-(5'-(5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azetidine-3,1'-isobenzofuran]-1-yl)-2-(methylsulfonyl)ethanone
  • the mixture is then filtered through filter aid (Celite 545) to remove the racemic material.
  • the sulfonamide remaining in solution is greater than 99% of a single isomer.
  • the organic solution is washed with water twice (2x1 L) and concentrated to an off-white solid. (138.2gm, 96%) Residual color can be removed by dissolving material in ethanol, stirring with 10 wt% charcoal (Darco G-60), filtering, and concentrating to a solid.
  • Chiral HPLC of the sulfonamide enantiomers Chiralpak IA column (250x3.0mm), isocratic 50/50 methyl tert -butyl ether/ ethanol with 0.2% diethylamine, flow rate 1.0mL/minute, detection at 260nm. Retention times: 8.5 minutes (active isomer product), 16.5 minutes (inactive minor isomer). The isolated solid is 99% active isomer and 1% or less of the inactive isomer. Further enantiomeric enrichment can be obtained by stirring in MTBE (for example) and filtering any solids which form. Product was identical to the first eluting enantiomer of the racemate under the preparative chiral SFC conditions described in Preparation 14.
  • Table 1 The Examples of Table 1 were named using ChemBioDraw Ultra 12.0 of ChemBioOffice 2010 and include:
  • the biological activity of the compounds of the present invention can be tested against hard tick larvae, soft ticks, fleas, and horn flies using the test methods described below.
  • Formula (1) compounds were dissolved in DMSO and aliquots added to citrated bovine blood in a membrane covered Petri dish pre-warmed to 37°C. Feeding tubes containing approximately 30-35 adult fleas were placed onto the Petri dishes. The fleas were allowed to feed for approximately 2 hours. Fleas were observed for knockdown and/or death at approximately 2 and 24 hours. Endpoint data were recorded as a lethal dose 80% (LD 80 ) in ⁇ g/mL.
  • Examples 1-3, 6, 29-30, 35, 37, 42-43, 45-46, 48, 49a, 52, and 54-60 had an LD 80 ⁇ 1 ⁇ g/mL; and Examples 5, 36, 48b, 51, and 53 had an LD 80 ⁇ 3 ⁇ g/mL.
  • Formula (1) compounds were dissolved in dimethylsulfoxide (DMSO) and aliquots added to citrated bovine blood in a membrane covered Petri dish.
  • the Petri dish was placed on a warming tray. Approximately 5 nymph stage ticks were placed onto the membrane, covered, and left to feed. Fed ticks were removed and placed into a Petri dish with sand. Fed ticks were observed at approximately 24, 48 and 72 hours for paralysis and/or death. Endpoint data was recorded as an ED 100 and/or an LD 100 in ⁇ g/mL. Positive control was fipronil and DMSO was used as the negative control.
  • DMSO dimethylsulfoxide
  • Examples 3, 6, 29, 35, 49a, and 51-59 had an LD 100 ⁇ 0.01 ⁇ g/mL; and Examples 1, 30, 36-37, 42-43, 45-46, 48, 50, and 60 had an LD 100 ⁇ 0.03 ⁇ g/mL.
  • Formula (1) compounds were dissolved in DMSO and aliquots added to citrated bovine blood in a membrane covered Petri dish. Approximately ten horn flies were placed onto each Petri dish and covered. The flies were then allowed to feed on the treated blood cell. Flies were held at approximately 80°F with a minimum of approximately 50% relative humidity. Flies were examined for knockdown and mortality at approximately 2 and 24 hours. Endpoint data was recorded as a lethal dose 90% (LD 90 ) in ⁇ g/mL.
  • LD 90 lethal dose 90%
  • Examples 6, 35, 37, and 49a had an LD 90 of ⁇ 0.3 ⁇ g/mL; Examples 29, 30, 45, 46, and 48 had an LD 90 of ⁇ 1 ⁇ g/mL; and Examples 1, 3, 42, and 43 had an LD 90 of ⁇ 3 ⁇ g/mL.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Claims (19)

  1. Composé de formule (1)
    Figure imgb0069
     dans lequel
    X est -0- et W est -CH2- ;
    R1a, R1b et R1c sont chacun indépendamment hydrogène, halogéno ou halogénoalkyle en C1-C6 ;
    R3 est halogénoalkyle en C1-C6;
    R4 est -C(O)R5 ;
    R5 est alkyle en C1-C6, alkyle en C0-C6-cycloalkyle en C3-C6, alkylhétéroaryle en C0-C6 ou alkylhétérocycle en C0-C6 ;
    dans lequel chacun des fragments R5 alkyle en C1-C6 ou alkyle en C0-C6-cycloalkyle en C3-C6 peut être optionnellement et indépendamment substitué par au moins un substituant choisi parmi cyano, halogéno, hydroxyle, oxo, alcoxy en C1-C6, halogénoalcoxy en C1-C6, halogénoalkyle en C1-C6, alkyle en C1-C6, hydroxyle-alkyle en C1-C6, -S(O)pRC, -SH, -S(O)pNRaRb, -NRaRb, -NRaC(O)Rb, -SC(O)R, -SCN ou -C(O)NRaRb ; et
    dans lequel chacun des fragments R5 alkylhétéroaryle en C0-C6 ou alkylhétérocycle en C0-C6 peut être en outre optionnellement substitué par au moins un substituant choisi parmi cyano, halogéno, oxo, =S, =NR7, hydroxyle, alcoxy en C1-C6, alkyle en C1-C6, halogénoalkyle en C1-C6, hydroxyle-alkyle en C1-C6, -SH, -S(O)pR et halogénoalcoxy en C1-C6 ;
    R7 est hydrogène, alkyle en C1-C6, hydroxyle, cyano, nitro, -S(O)pRc ou alcoxy en C1-C6 ;
    R est alkyle en C1-C6 ou cycloalkyle en C3-C6 optionnellement substitué par au moins un substituant halogéno ;
    Ra est hydrogène, alkyle en C1-C6 ou alkyle en C0-C3-cycloalkyle en C3-C6 ; dans lequel alkyle et alkylcycloalkyle sont optionnellement substitués par cyano ou au moins un substituant halogéno ;
    Rb est hydrogène, alkyle en C1-C6, cycloalkyle en C3-C6, alkylphényle en C0-C3, alkylhétéroaryle en C0-C3 ou alkylhétérocycle en C0-C3, chacun étant optionnellement substitué, lorsque cela est chimiquement possible, par au moins un substituant choisi parmi hydroxyle, cyano, halogéno ou -S(O)pR ;
    RC est alkyle en C1-C6, halogénoalkyle en C1-C6, halogénoalkyle en C1-C6-cycloalkyle en C3-C6, alkyle en C0-C3-cycloalkyle en C3-C6, alkylphényle en C0-C3, alkylhétéroaryle en C0-C3 ou alkylhétérocycle en C0-C3, chacun étant optionnellement substitué par au moins un substituant choisi parmi cyano, halogéno, hydroxyle, oxo, alcoxy en C1-C6, halogénoalcoxy en C1-C6, halogénoalkyle en C1-C6, -S(O)pR, -SH, - S(O)pNRaRb, -NRaRb, -NRaRb, -NRaC(O)Rb, -SC(O)R, -SCN ou -C(O)NRaRb;
    p est l'entier 0, 1 ou 2 ; et n est l'entier 0 ;
    ses stéréoisomères et ses sels vétérinairement acceptables.
  2. Composé selon la revendication 1, dans lequel R3 est -CF3 ;
    ses stéréoisomères et ses sels pharmaceutiquement acceptables.
  3. Composé selon l'une quelconque des revendications précédentes choisi dans le groupe constitué de
    1-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-((trifluorométhyl)thio)éthanone ;
    (5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)(1-oxidothiétan-3-yl)méthanone ;
    (5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)(1,1-dioxidothiétan-3-yl)méthanone ;
    1-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylthio)éthanone ;
    (R)-1-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylthio)éthanone ;
    (S)-1-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylthio)éthanone ;
    1-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylsulfinyl)éthanone ;
    (R)-1-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylsulfinyl)éthanone ;
    (S)-1-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylsulfinyl)éthanone ;
    1-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylsulfonyl)éthanone ;
    (R)-1-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylsulfonyl)éthanone ;
    (S)-1-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylsulfonyl)éthanone ;
    1-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-méthylpropan-1-one ;
    1-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-hydroxyéthanone ;
    cyclobutyl(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)méthanone ;
    (5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)(1-hydroxycyclopropyl)méthanone ;
    N-(2-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-oxoéthyl)formamide ;
    1-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)éthanone ;
    1- (5' - (5- (3, 5-dichloro-4-fluorophényl) -5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)propan-1-one ;
    1-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-hydroxy-2-méthylpropan-1-one ;
    2-cyclopropyl-1-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)éthanone ;
    1-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2,2-diméthylpropan-1-one ;
    (5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)(1-(trifluorométhyl)cyclopropyl)-méthanone ;
    1-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-3-hydroxy-2-méthylpropan-1-one ;
    1-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(3-méthyl-1H-pyrazol-1-yl)éthanone ;
    1-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-3-méthylbutan-1-one ;
    1-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(1H-pyrazol-1-yl)éthanone ;
    1-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-3-hydroxybutan-1-one ;
    cyclopropyl(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)méthanone ;
    1-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)butan-1-one ;
    5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)(thiétan-3-yl)méthanone ;
    (5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)(1,1-dioxidothiétan-3-yl)méthanone ;
    (R)-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)(1,1-dioxidothiétan-3-yl)méthanone ;
    (S)-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)(1,1-dioxidothiétan-3- yl)méthanone ;
    2-(méthylsulfonyl)-1-(5'-(5-(3,4,5-trichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)éthanone ;
    1-(5'-(5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylsulfonyl)éthanone ;
    1-(5'-(5-(3-chloro-5-(trifluorométhyl)phényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylsulfonyl)éthanone ;
    1-(5'-(5-(3,4-dichloro-5-(trifluorométhyl)phényl)-5-(trifluorométhyl)-4,5-dihydro-isoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylsulfonyl)-éthanone ;
    1-(5'-(5-(4-bromo-3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylsulfonyl)éthanone ;
    1-(5'-(5-(3,5-bis(trifluorométhyl)phényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylsulfonyl)éthanone ;
    (R)-1-(5'-(5-(3,5-bis(trifluorométhyl)phényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylsulfonyl)éthanone ;
    (S)-1-(5'-(5-(3,5-bis(trifluorométhyl)phényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylsulfonyl)éthanone ;
    1-(5'-(5-(3-bromo-5-chlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylsulfonyl)éthanone ;
    1-(5'-(5-(4-chloro-3,5-bis(trifluorométhyl)phényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylsulfonyl)éthanone ;
    1-(5'-(5-(3-chloro-5-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylsulfonyl)éthanone ;
    1-(5'-(5-(3-chloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylsulfonyl)éthanone ;
    (R)-1-(5'-(5-(3-chloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylsulfonyl)éthanone ;
    (S)-1-(5'-(5-(3-chloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylsulfonyl)éthanone ;
    2-(méthylsulfonyl)-1-(5'-(5-(trifluorométhyl)-5-(3-(trifluorométhyl)phényl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)éthanone ;
    (R)-2-(méthylsulfonyl)-1-(5'-(5-(trifluorométhyl)-5-(3-(trifluorométhyl)phényl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)éthanone ; et
    (S)-2-(méthylsulfonyl)-1-(5'-(5-(trifluorométhyl)-5-(3-(trifluorométhyl)phényl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)éthanone, ou un stéréoisomère de celui-ci, ou un sel vétérinairement acceptable de celui-ci.
  4. Composé selon la revendication 3 choisi parmi :
    1-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylthio)éthanone ;
    (R)-1-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylthio)éthanone ;
    (S)-1-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylthio)éthanone ;
    1-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylsulfinyl)éthanone ;
    (R)-1-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylsulfinyl)éthanone ;
    (S)-1-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylsulfinyl)éthanone ;
    1-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylsulfonyl)éthanone ;
    (R)-1-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylsulfonyl)éthanone ;
    (S)-1-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylsulfonyl)éthanone ;
    (5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)(1,1-dioxidothiétan-3-yl)méthanone ;
    (R)-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)(1,1-dioxidothiétan-3-yl)méthanone ;
    (S)-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)(1,1-dioxidothiétan-3-yl)méthanone ;
    1-(5'-(5-(3,5-bis(trifluorométhyl)phényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylsulfonyl)éthanone ;
    (R)-1-(5'-(5-(3,5-bis(trifluorométhyl)phényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylsulfonyl)éthanone ;
    (S)-1-(5'-(5-(3,5-bis(trifluorométhyl)phényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylsulfonyl)éthanone ;
    1-(5'-(5-(3-chloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylsulfonyl)éthanone ;
    (R)-1-(5'-(5-(3-chloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylsulfonyl)éthanone ;
    (S)-1-(5'-(5-(3-chloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylsulfonyl)éthanone ;
    2-(méthylsulfonyl)-1-(5'-(5-(trifluorométhyl)-5-(3-(trifluorométhyl)phényl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)éthanone ;
    (R)-2-(méthylsulfonyl)-1-(5'-(5-(trifluorométhyl)-5-(3-(trifluorométhyl)phényl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)éthanone ; et
    (S)-2-(méthylsulfonyl)-1-(5'-(5-(trifluorométhyl)-5-(3-(trifluorométhyl)phényl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)éthanone, ou un stéréoisomère de celui-ci, ou un sel vétérinairement acceptable de celui-ci.
  5. Composé selon la revendication 4 choisi parmi :
    1-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylsulfonyl)éthanone et (S)-1-(5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-yl)-2-(méthylsulfonyl)éthanone.
  6. Composition pharmaceutique ou vétérinaire comprenant un composé tel que défini dans l'une quelconque des revendications 1 à 5.
  7. Composition pharmaceutique ou vétérinaire selon la revendication 6, comprenant en outre un excipient, diluant ou support vétérinairement acceptable.
  8. Composition vétérinaire selon la revendication 6 ou 7, comprenant en outre au moins un agent vétérinaire supplémentaire.
  9. Composition vétérinaire selon la revendication 8, dans laquelle ledit agent vétérinaire supplémentaire est choisi dans le groupe constitué d'abamectine, ivermectine, avermectine, moxidectine, émamectine, éprinomectine, sélamectine, doramectine, némadectine, albendazole, cambendazole, fenbendazole, flubendazole, mebendazole, oxfenbendazole, oxibendazole, parbendazole, tétramisole, lévamisole, pyrantel pamoate, oxantel, morantel, indoxacarb, closantel, triclabendazole, clorsulon, réfoxanide, niclosamide, praziquantel, epsiprantel, 2-désoxoparaherquamide, pyripole, pyrafluprole, lufenuron, spiromésifène, tébufenozide, spinosad, spinetoram, imidacloprid, dinotéfurane, métaflumizone, thibendiamide, chlorantraniliprole, indoxacarb, pyridalyle, pyrimidifène, pyrifluquinazon, oxime de milbemycine, milbemycine, démiditraz, amitraz, fipronile, méthoprène, hydroprène, kinoprène, perméthrine et pyréthrine, ou des mélanges de ceux-ci.
  10. Composition vétérinaire selon la revendication 8, dans laquelle ledit agent vétérinaire supplémentaire est choisi dans le groupe constitué de moxidectine, pamoate de pyrantel, milbémycine, oxime de milbémycine ou de mélanges de ceux-ci.
  11. Composé selon l'une quelconque des revendications 1 à 5 pour utilisation dans le traitement d'une infection ou infestation parasitaire chez un animal.
  12. Composé destiné à être utilisé selon la revendication 11, le composé étant administré par voie topique, orale ou sous-cutanée.
  13. Composé destiné à être utilisé selon la revendication 11, dans lequel ledit animal est un animal de compagnie.
  14. Procédé pour la préparation d'un composé de formule (63)
    Figure imgb0070
    R1a, R1b et R1c sont chacun indépendamment hydrogène, halogéno ou halogénoalkyle en C1-C6 ;
    R5 est alkyle en C1-C6, alkyle en C0-C6-cycloalkyle en C3-C6, alkylhétéroaryle en C0-C6 ou alkylhétérocycle en C0-C6 ;
    R7 est hydrogène, alkyle en C1-C6, hydroxyle, cyano, nitro, -S(O)pRC ou alcoxy en C1-C6 ;
    R est alkyle en C1-C6 ou cycloalkyle en C3-C6 optionnellement substitué par au moins un substituant halogéno ;
    Ra est hydrogène, alkyle en C1-C6 ou alkyle en C0-C3-cycloalkyle en C3-C6 ; dans lequel alkyle et alkylcycloalkyle sont optionnellement substitués par cyano ou au moins un substituant halogéno ;
    Rb est hydrogène, alkyle en C1-C6, cycloalkyle en C3-C6, alkylphényle en C0-C3, alkylhétéroaryle en C0-C3 ou alkylhétérocycle en C0-C3, chacun étant optionnellement substitué, lorsque cela est chimiquement possible, par au moins un substituant choisi parmi hydroxyle, cyano, halogéno ou -S(O)pR ;
    RC est alkyle en C1-C6, halogénoalkyle en C1-C6, halogénoalkyle en C1-C6-cycloalkyle en C3-C6, alkyle en C0-C3-cycloalkyle en C3-C6, alkylphényle en C0-C3, alkylhétéroaryle en C0-C3 ou alkylhétérocycle en C0-C3, chacun étant optionnellement substitué par au moins un substituant choisi parmi cyano, halogéno, hydroxyle, oxo, alcoxy en C1-C6, halogénoalcoxy en C1-C6, halogénoalkyle en C1-C6, -S(O)pR, -SH, - S(O)pNRaRb, -NRaRb, -NRaC(O)Rb, -SC(O)R, -SCN ou -C(O)NRaRb;
    dans lequel le fragment R5 alkyle en C1-C6 ou alkyle en C0-C6-cycloalkyle en C3-C6 peut être optionnellement et indépendamment substitué par au moins un substituant choisi parmi cyano, halogéno, hydroxyle, oxo, alcoxy en C1-C6, halogénoalcoxy en C1-C6, halogénoalkyle en C1-C6, alkyle en C1-C6, hydroxyle-alkyle en C1-C6, -S(O)pRC, -SH, -S(O)pNRaRb, -NRaRb, -NRaC(O)Rb, -SC(O)R, -SCN ou -C(O)NRaRb ; et
    dans lequel le fragment R5 alkylhétéroaryle en C0-C6 ou alkylhétérocycle en C0-C6 peut être en outre optionnellement substitué par au moins un substituant choisi parmi cyano, halogéno, oxo, =S, =NR7, hydroxyle, hydroxyle-alkyle en C1-C6, alcoxy en C1-C6, alkyle en C1-C6, halogénoalkyle en C1-C6, -SH, -S(O)pR et halogénoalcoxy en C1-C6 ;
    n est l'entier 0 ;
    p est l'entier 0, 1 ou 2 ; et
    * indique un centre chiral,
    ses stéréoisomères, et ses sels pharmaceutiquement acceptables ;
    ledit procédé comprenant, optionnellement dans un solvant,
    a) la métallation d'un dérivé d'iodobromobenzyle de formule 57 avec un réactif de Grignard ou un échange halogène-métal avec un alkyllithium et la mise en réaction avec une azétidinone protégée dans un traitement monotope ou dans un traitement par étapes pour fournir un composé de formule 58, dans laquelle Y2 est brome, chlore, iode, hydroxyle ou un groupe partant sulfonate ;
    Figure imgb0071
    b) la condensation catalysée par palladium d'un composé de formule 58 avec un éther vinylique pour fournir un composé de formule 59, où R8 est un alkyle en C1-C6 :
    Figure imgb0072
    c) la condensation d'un composé de formule 59 avec une trifluoroacétophénone substituée de formule 56 pour fournir un composé de formule 60 ;
    Figure imgb0073
    d) l'ajout d'hydroxylamine à un composé de formule 60 et la cyclisation en la présence d'un catalyseur chiral à base de quinine pour fournir un composé de formule 61 ;
    Figure imgb0074
    e) le retrait du groupe protecteur azétidine du composé de formule 61 pour fournir un composé de formule 62 ; et
    Figure imgb0075
    f) le couplage du composé de formule 62 avec un acide ou chlorure d'acide dans des conditions de formation d'amide standards pour fournir un composé de formule 63
    Figure imgb0076
  15. Procédé selon la revendication 14, dans lequel
    le fragment R5 alkyle en C1-C6 ou alkyle en C0-C6-cycloalkyle en C3-C6 peut être optionnellement et indépendamment substitué par au moins un substituant choisi parmi halogéno, hydroxyle, hydroxyle-alkyle en C1-C6, halogénoalkyle en C1-C6, alkyle en C1-C6 ou -S(O)pRC ; et
    le fragment R5 alkylhétéroaryle en C0-C6 ou alkylhétérocycle en C0-C6 peut être en outre optionnellement substitué par au moins un substituant choisi parmi oxo, hydroxyle, hydroxyle-alkyle en C1-C6, alkyle en C1-C6 ou halogénoalkyle en C1-C6 ;
    RC est alkyle en C1-C6 ;
    n est l'entier 0 ; et
    p est l'entier 0, 1 ou 2 ;
    ses stéréoisomères et ses sels vétérinairement acceptables.
  16. Procédé selon la revendication 15, dans lequel
    R1a, R1b et R1c sont chacun indépendamment hydrogène, chloro, fluoro, bromo ou trifluorométhyle ;
    R5 est méthyle, éthyle, propyle, isopropyle, butyle, isobutyle, t-butyle, cyclopropyle ou cyclobutyle, dans lequel chaque substituant peut être optionnellement et indépendamment substitué par au moins un substituant choisi parmi halogéno, hydroxyle, halogénoalkyle en C1-C6, alkyle en C1-C6, ou -S(O)pRC ; ou R5 est thiétanyle, pyrazolyle ou -CH2pyrazolyle, dans lequel chaque substituant peut en outre être optionnellement substitué par au moins un substituant choisi parmi oxo ou alkyle en C1-C6 ; et
    RC est méthyle ou éthyle ;
    ses stéréoisomères et ses sels vétérinairement acceptables.
  17. Procédé selon la revendication 16, dans lequel
    R1a et R1c sont chacun chloro, R1b est fluoro ;
    R5 est -CH2S(O)2CH3 ;
    leurs stéréoisomères et leurs sels vétérinairement acceptables.
  18. Procédé selon la revendication 14, comprenant optionnellement dans un solvant, dans lequel le dérivé d'iodobromobenzyle est 4-bromo-2-(chlorométhyl)-1-iodobenzène et l'azétidinone protégée est un ester tert-butylique d'acide 3-oxooazétidine-1-carboxylique ou une 1-benzhydrylazétidin-3-one.
  19. Composé choisi dans le groupe constitué de :
    tert-butyl 5'-bromo-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-carboxylate ;
    1-benzhydryl-5'-bromo-3'H-spiro[azétidine-3,1'-isobenzofurane] ;
    tert-butyl 5'-acétyl-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-carboxylate ;
    1-(l-benzhydryl-3'H-spiro[azétidine-3,1'-isobenzofuran]-5'-yl)éthanone ;
    tert-butyl 5'-(3-(3,5-dichloro-4-fluorophényl)-4,4,4-trifluorobut-2-énoyl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-carboxylate ;
    (R)-tert-butyl 5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-carboxylate ;
    (S)-tert-butyl 5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-carboxylate ;
    (E/2)-1-(1-benzhydryl-3'H-spiro[azétidine-3,1'-isobenzofuran]-5'-yl)-3-(3,5-dichloro-4-fluorophényl)-4,4,4-trifluorobut-2-én-1-one ;
    tert-butyl 5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]-1-carboxylate ;
    (R)-5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]para-toluène sulfonate ;
    (S)-5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]para-toluène sulfonate ;
    1-benzhydryl-5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofurane] ;
    (R)-1-benzhydryl-5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofurane]
    (S)-1-benzhydryl-5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofurane] ; et
    5'-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azétidine-3,1'-isobenzofuran]para-toluène sulfonate,
    ou un stéréoisomère de celui-ci.
EP12709376.3A 2011-03-10 2012-02-23 Dérivés spirocycliques d'isoxazoline en tant qu'agents antiparasitaires Active EP2683723B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
HRP20160601TT HRP20160601T1 (hr) 2011-03-10 2012-02-23 Spirociklički derivati izoksazolina kao antiparazitska sredstva
MEP-2016-125A ME02412B (fr) 2011-03-10 2012-02-23 Dérivés d'isoxazolines spirocycliques à titre d'agents antiparasitaires
PL12709376T PL2683723T3 (pl) 2011-03-10 2012-02-23 Spirocykliczne pochodne izoksazoliny jako środki przeciwpasożytnicze
RS20160432A RS54860B1 (sr) 2011-03-10 2012-02-23 Spirociklični derivati izoksazolina kao antiparazitska sredstva
SI201230583A SI2683723T1 (sl) 2011-03-10 2012-02-23 Spirociklični izoksazolinski derivati kot antiparazitiki

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161451256P 2011-03-10 2011-03-10
US201161489913P 2011-05-25 2011-05-25
US201161490804P 2011-05-27 2011-05-27
PCT/IB2012/050842 WO2012120399A1 (fr) 2011-03-10 2012-02-23 Dérivés d'isoxazolines spirocycliques à titre d'agents antiparasitaires

Publications (2)

Publication Number Publication Date
EP2683723A1 EP2683723A1 (fr) 2014-01-15
EP2683723B1 true EP2683723B1 (fr) 2016-05-25

Family

ID=45852624

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12709376.3A Active EP2683723B1 (fr) 2011-03-10 2012-02-23 Dérivés spirocycliques d'isoxazoline en tant qu'agents antiparasitaires

Country Status (26)

Country Link
US (1) US8466115B2 (fr)
EP (1) EP2683723B1 (fr)
JP (1) JP5806743B2 (fr)
KR (1) KR101565853B1 (fr)
CN (1) CN103517907B (fr)
AR (1) AR085649A1 (fr)
AU (1) AU2012226475C1 (fr)
BR (1) BR112013023068B8 (fr)
CA (1) CA2828397C (fr)
CL (1) CL2013002516A1 (fr)
CO (1) CO6761337A2 (fr)
CY (1) CY1117987T1 (fr)
ES (1) ES2585555T3 (fr)
HR (1) HRP20160601T1 (fr)
HU (1) HUE029810T2 (fr)
ME (1) ME02412B (fr)
MX (1) MX2013010336A (fr)
PH (1) PH12013501831B1 (fr)
PL (1) PL2683723T3 (fr)
PT (1) PT2683723T (fr)
RS (1) RS54860B1 (fr)
RU (1) RU2566083C3 (fr)
SI (1) SI2683723T1 (fr)
UY (1) UY33943A (fr)
WO (1) WO2012120399A1 (fr)
ZA (1) ZA201306817B (fr)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL232463B1 (pl) * 2012-02-06 2019-06-28 Merial Inc Miękka, nadająca się do żucia kompozycja weterynaryjna do leczenia i/lub zapobiegania infekcji lub inwazji pasożytniczej u zwierzęcia oraz jej zastosowanie
JO3626B1 (ar) 2012-02-23 2020-08-27 Merial Inc تركيبات موضعية تحتوي على فيبرونيل و بيرميثرين و طرق استخدامها
AU2013308887B2 (en) 2012-08-31 2015-11-12 Zoetis Services Llc Crystalline forms of 1-(5'-(5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azetidine-3,1'-isobenzofuran]-1-yl)-2-(methylsulfonyl)ethanone
EP2900065A1 (fr) 2012-09-04 2015-08-05 Zoetis LLC Dérivés d'isoxazoline spirocyclique pour le traitement des poux de mer
HK1210473A1 (en) 2012-09-07 2016-04-22 Zoetis Services Llc Spirocyclic isoxazolines as antiparasitic agents
BR112015004826A2 (pt) * 2012-09-07 2017-07-04 Zoetis Llc derivados espirocíclicos como agentes antiparasíticos
BR112015004698B8 (pt) * 2012-09-07 2022-11-22 Zoetis Llc Composições sinérgicas parasitícidas e seus usos
CN104918944B (zh) * 2012-11-21 2017-05-10 硕腾服务有限责任公司 螺环异噁唑啉衍生物的合成
PT2953942T (pt) 2013-02-06 2018-01-17 Bayer Cropscience Ag Derivados de pirazol substituídos com halogéneo como agentes pesticidas
EP2999339B1 (fr) * 2013-05-20 2019-06-19 Zoetis Services LLC Compositions antiparasitaires à action prolongée à base d'une spiro-oxazoline
US10350196B2 (en) 2013-09-30 2019-07-16 Zoetis Services Llc Long-acting spiro-isoxazoline formulations
US9371293B2 (en) 2013-10-25 2016-06-21 Sumitomo Chemical Company, Limited Isoxazoline compound composition
EP3063144B1 (fr) 2013-11-01 2021-09-08 Boehringer Ingelheim Animal Health USA Inc. Composés d'isoxazoline antiparasitaires et pesticides
JP6581586B2 (ja) 2013-12-20 2019-09-25 インターベット インターナショナル ベー． フェー． イソオキサゾリン組成物および動物における寄生虫侵襲の予防または処置におけるその使用
ES2683693T3 (es) 2014-01-03 2018-09-27 Bayer Animal Health Gmbh Nuevas pirazolil-heteroarilamidas como agentes plaguicidas
CA2945766C (fr) 2014-04-17 2023-09-26 Merial, Inc. Utilisation de composes de malononitrile pour proteger des animaux contre les parasites
US10208015B2 (en) 2014-07-15 2019-02-19 Bayer Animal Health Gmbh Aryl-triazolyl pyridines as pest control agents
WO2016022066A1 (fr) 2014-08-04 2016-02-11 Jerry Tan Eye Surgery Pte Ltd Compositions pharmaceutiques pour blépharite et encroûtement des paupières liés à demodex
ES2887302T3 (es) 2014-10-31 2021-12-22 Boehringer Ingelheim Animal Health Usa Inc Composiciones parasiticidas que comprenden fipronil
AU2015371175B2 (en) * 2014-12-22 2021-03-04 Intervet International B.V. Use of isoxazoline compounds for treating demodicosis
KR20170102359A (ko) * 2015-01-16 2017-09-08 아비스타 파마 솔루션즈, 아이엔씨. 항기생충 화합물
UY36570A (es) 2015-02-26 2016-10-31 Merial Inc Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas
EP3280413A1 (fr) 2015-04-08 2018-02-14 Merial, Inc. Formulations injectables à action prolongée comprenant un principe actif isoxazoline, méthodes et utilisations de celles-ci
US10081656B2 (en) 2015-05-20 2018-09-25 Merial, Inc. Anthelmintic depsipeptide compounds
UY37137A (es) 2016-02-24 2017-09-29 Merial Inc Compuestos antiparasitarios de isoxazolina, formulaciones inyectables de acción prolongada que los comprenden, métodos y usos de los mismos
US20190077809A1 (en) 2016-03-09 2019-03-14 Basf Se Spirocyclic Derivatives
CN108697089A (zh) * 2016-03-11 2018-10-23 巴斯夫欧洲公司 防除植物害虫的方法
CA3019947A1 (fr) * 2016-04-06 2017-10-12 Merial, Inc. Procede de preparation de composes d'isoxazoline enantiomeriquement enrichis et de solvate de toluene cristallin de (s)-afoxolaner
US10556909B2 (en) 2016-05-20 2020-02-11 Avista Pharma Solutions, Inc. Synthetic process and intermediates
WO2018009751A1 (fr) * 2016-07-08 2018-01-11 Avista Pharma Solutions, Inc. Composés antiparasitaires
WO2018039508A1 (fr) 2016-08-25 2018-03-01 Merial, Inc. Procédé de réduction d'effets indésirables dans des traitements antiparasitaires
CN110381738B (zh) 2016-10-14 2021-07-16 勃林格殷格翰动物保健美国公司 农药的和杀寄生物的乙烯基异噁唑啉化合物
WO2018093920A1 (fr) 2016-11-16 2018-05-24 Merial, Inc. Composés depsipeptidiques anthelminthiques
WO2018162312A1 (fr) * 2017-03-10 2018-09-13 Basf Se Dérivés spirocycliques
WO2018166855A1 (fr) 2017-03-16 2018-09-20 Basf Se Dihydroisoxazoles à substitution hétérobicyclique
WO2019036407A1 (fr) 2017-08-14 2019-02-21 Merial, Inc. Composés de pyrazole-isoxazoline à activité pesticide et parasiticide
JP7305620B2 (ja) 2017-09-06 2023-07-10 バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 動物寄生虫（ａｎｉｍａｌ ｐａｒａｓｉｔｅｓ）の防除および予防のための局所投与製剤
US10807992B2 (en) 2017-11-16 2020-10-20 Avista Pharma Solutions, Inc. Single enantiomer antiparasitic compounds
DK3723739T3 (da) 2017-12-15 2024-06-17 Tarsus Pharmaceuticals Inc Isoxazolin-parasiticidformuleringer og deres anvendelse til behandling af blepharitis
WO2019157241A1 (fr) 2018-02-08 2019-08-15 Boehringer Ingelheim Animal Health USA Inc. Compositions parasiticides comprenant de l'éprinomectine et du praziquantel, procédés et utilisations associés
HRP20230243T1 (hr) 2018-06-07 2023-04-14 Idorsia Pharmaceuticals Ltd Alkoksi supstituirani derivati piridinila kao antagonisti receptora lpa1 i njihova uporaba u liječenju fibroze
PE20211275A1 (es) 2018-07-09 2021-07-19 Boehringer Ingelheim Animal Health Usa Inc Compuestos heterociclicos antihelminticos
CA3113874A1 (fr) 2018-10-29 2020-05-07 Basf Se Procede de preparation de composes d'aldol optiquement enrichis
US20210380569A1 (en) 2018-11-06 2021-12-09 Basf Se Process for Preparation of Optically Enriched Isoxazolines
EP3883648A1 (fr) 2018-11-20 2021-09-29 Boehringer Ingelheim Animal Health USA Inc. Composé indazolylcyanoéthylamino, compositions associées, procédé de fabrication et procédés d'utilisation de celui-ci
US11440861B2 (en) 2018-12-04 2022-09-13 Basf Se Process for preparation of 5-bromo-1,3-dichloro-2-fluoro-benzene
NZ776819A (en) 2019-01-16 2023-04-28 Boehringer Ingelheim Animal Health Usa Inc Topical compositions comprising a neonicotinoid and a macrocyclic lactone, methods and uses thereof
KR20220002890A (ko) 2019-03-19 2022-01-07 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 구충성 아자-벤조티오펜 및 아자-벤조푸란 화합물
AR119162A1 (es) 2019-06-18 2021-12-01 Idorsia Pharmaceuticals Ltd Derivados de piridin-3-ilo
AU2020408351A1 (en) * 2019-12-18 2022-08-11 Elanco Tiergesundheit Ag Isoxazoline derivatives as pesticides
CN111253331B (zh) * 2020-03-17 2022-03-08 南京林业大学 一种以二氢查尔酮为原料合成螺异噁唑啉的方法
AU2021278871A1 (en) 2020-05-28 2023-01-19 Boehringer Ingelheim Animal Health USA Inc. Bi-modal release intra-ruminal capsule device and methods of use thereof
MX2022015038A (es) 2020-05-29 2023-01-04 Boehringer Ingelheim Animal Health Usa Inc Compuestos heterociclicos como anthelminticos.
CN111675668B (zh) * 2020-06-28 2022-09-13 南京林业大学 一种tempo催化的以肟类化合物为原料合成螺异噁唑啉的反应方法
US20230257370A1 (en) 2020-07-24 2023-08-17 Elanco Us Inc. Process for making an isoxazoline compound and intermediate thereof
JP2024504208A (ja) 2020-12-21 2024-01-30 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー イソオキサゾリン化合物を含む殺寄生虫首輪
US20240116854A1 (en) 2021-01-27 2024-04-11 Intervet Inc. Cyclopropylamide compounds against parasites in fish
JP2024511258A (ja) 2021-01-27 2024-03-13 コルテバ アグリサイエンス エルエルシー 魚における寄生生物に対するシクロプロピルアミド化合物
WO2022238575A1 (fr) 2021-05-14 2022-11-17 Syngenta Crop Protection Ag Lutte antiparasitaire contre les insectes, les acariens et les nématodes
CA3222495A1 (fr) 2021-06-16 2022-12-22 Elanco Tiergesundheit Ag Pesticides (thi)oxazoline
JP2024523313A (ja) 2021-06-16 2024-06-28 エランコ・ティアゲゾンタイト・アーゲー イソオキサゾリン殺害虫剤
WO2022268815A1 (fr) 2021-06-24 2022-12-29 Syngenta Crop Protection Ag Lutte contre les insectes, les acariens et les nématodes nuisibles
WO2022268813A1 (fr) 2021-06-24 2022-12-29 Syngenta Crop Protection Ag Lutte contre les insectes, les acariens et les nématodes nuisibles
US20240389596A1 (en) 2021-09-23 2024-11-28 Syngenta Crop Protection Ag Insect, acarina and nematode pest control
WO2023156938A1 (fr) 2022-02-17 2023-08-24 Boehringer Ingelheim Vetmedica Gmbh Procédé et système pour fournir un dispositif d'expédition de produit fluide
WO2023203038A1 (fr) 2022-04-19 2023-10-26 Syngenta Crop Protection Ag Lutte contre les insectes, les acariens et les nématodes nuisibles
FI20225388A1 (en) 2022-05-05 2023-11-06 Equinorm Ltd New heterocyclic compounds, preparation methods and their uses
DK182016B1 (en) 2023-03-13 2025-05-28 Zoetis Services Llc Degradation of isoxazolines in ozonated sea water
NO20240925A1 (en) 2023-09-15 2025-03-17 Evah Atlantic Inc Dihydroisoxazole compound for use in reducing ectoparasite infestations on fish
WO2025257633A1 (fr) 2024-06-12 2025-12-18 Boehringer Ingelheim Vetmedica Gmbh Formulations injectables à action prolongée contenant de l'huile de ricin et procédés d'utilisation associés

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554753A (en) 1993-08-25 1996-09-10 Indiana University Foundation Catalytic enantioselective synthesis of α-amino acid derivatives by phase-transfer catalysis
TW524667B (en) 1996-12-05 2003-03-21 Pfizer Parasiticidal pyrazoles
GB0329314D0 (en) 2003-12-18 2004-01-21 Pfizer Ltd Substituted arylpyrazoles
BRPI0508140B1 (pt) * 2004-03-05 2015-03-17 Nissan Chemical Ind Ltd Composto benzamida substituída por isoxazolina da fórmula (1); da fórmula (2) substituído por 3,5-bis (aril substituído); da fórmula (4) substituída por alquinibenzeno ou um sal do mesmo; "pesticida, agroquímico, inseticida, parasiticida contendo como ingrediente ativo um ou mais composto benzamida substituída por isoxazolina e sal do mesmo"
PL1904477T3 (pl) 2005-07-14 2009-07-31 Hoffmann La Roche Pochodne indolo-3-karbonylo-spiro-piperydyny jako antagoniści receptora V1a
TW200803740A (en) 2005-12-16 2008-01-16 Du Pont 5-aryl isoxazolines for controlling invertebrate pests
DE602007006288D1 (de) * 2006-03-10 2010-06-17 Nissan Chemical Ind Ltd Substituierte isoxazolin-verbindung und schädlingsbekämpfungsmittel
US8575167B2 (en) 2007-02-06 2013-11-05 Takeda Pharmaceutical Company Limited Spiro compounds having stearoyl-CoA desaturase action
US8372867B2 (en) 2007-04-10 2013-02-12 Bayer Cropscience Ag Insecticidal aryl isoxazoline derivatives
JP5184057B2 (ja) * 2007-08-10 2013-04-17 日本曹達株式会社 含窒素複素環化合物および有害生物防除剤
JP5365806B2 (ja) 2007-09-10 2013-12-11 日産化学工業株式会社 置換イソキサゾリン化合物及び有害生物防除剤
JP5365807B2 (ja) 2007-11-12 2013-12-11 日産化学工業株式会社 光学活性イソキサゾリン化合物の触媒的不斉合成方法
JP2009286773A (ja) * 2008-03-14 2009-12-10 Bayer Cropscience Ag 殺虫性縮環式アリール類
EP2331535B1 (fr) * 2008-09-04 2015-07-22 Syngenta Participations AG Composés insecticides
WO2010027051A1 (fr) * 2008-09-04 2010-03-11 日産化学工業株式会社 Composé acétophénone substitué, son procédé de production, et son utilisation
CN102149696A (zh) 2008-09-18 2011-08-10 日本曹达株式会社 含氮杂环化合物及有害生物防除剂
WO2010084067A2 (fr) 2009-01-22 2010-07-29 Syngenta Participations Ag Composés insecticides
MX2012009707A (es) 2010-02-25 2012-09-12 Syngenta Ltd Proceso para preparar derivados isoxazolinicos.

Also Published As

Publication number Publication date
CY1117987T1 (el) 2017-05-17
AR085649A1 (es) 2013-10-16
HRP20160601T1 (hr) 2016-07-01
AU2012226475C1 (en) 2015-08-06
ME02412B (fr) 2016-09-20
AU2012226475A1 (en) 2013-09-12
UY33943A (es) 2012-10-31
HK1190393A1 (zh) 2014-07-04
NZ614547A (en) 2014-12-24
KR20140017590A (ko) 2014-02-11
KR101565853B1 (ko) 2015-11-05
AU2012226475B2 (en) 2015-04-30
CN103517907A (zh) 2014-01-15
BR112013023068B8 (pt) 2022-11-22
CA2828397A1 (fr) 2012-09-13
BR112013023068B1 (pt) 2020-11-17
RU2013139630A (ru) 2015-04-20
CO6761337A2 (es) 2013-09-30
EP2683723A1 (fr) 2014-01-15
ZA201306817B (en) 2016-07-27
RU2566083C2 (ru) 2015-10-20
RU2566083C3 (ru) 2017-11-09
CA2828397C (fr) 2015-10-13
PH12013501831B1 (en) 2019-06-14
CN103517907B (zh) 2016-07-06
MX2013010336A (es) 2013-10-03
SI2683723T1 (sl) 2016-07-29
CL2013002516A1 (es) 2014-06-13
US20120232026A1 (en) 2012-09-13
JP5806743B2 (ja) 2015-11-10
PT2683723T (pt) 2016-08-05
PL2683723T3 (pl) 2017-07-31
RS54860B1 (sr) 2016-10-31
WO2012120399A1 (fr) 2012-09-13
US8466115B2 (en) 2013-06-18
HUE029810T2 (en) 2017-03-28
ES2585555T3 (es) 2016-10-06
JP2014508773A (ja) 2014-04-10
BR112013023068A2 (pt) 2016-07-26
PH12013501831A1 (en) 2013-11-18

Similar Documents

Publication Publication Date Title
EP2683723B1 (fr) Dérivés spirocycliques d'isoxazoline en tant qu'agents antiparasitaires
US9131697B2 (en) Spirocyclic isoxazolines as antiparasitic agents
CA2881844A1 (fr) Derives spirocycliques en tant qu'agents antiparasitaires
JP6049866B2 (ja) 駆虫剤としてのアゼチジン誘導体
EP2814825B1 (fr) Dérivés de dihydrofurane à substitution azétidine en tant qu'agents antiparasitaires
NZ614547B2 (en) Spirocyclic isoxazoline derivatives as antiparasitic agents
HK1190393B (en) Spirocyclic isoxazoline derivatives as antiparasitic agents

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20131008

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

17Q First examination report despatched

Effective date: 20141029

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ZOETIS SERVICES LLC

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20151210

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20160601

Country of ref document: HR

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 802240

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160615

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM AND CO. AG PATENT- UND MARKENANWAELTE , CH

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20160601

Country of ref document: HR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602012018933

Country of ref document: DE

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2683723

Country of ref document: PT

Date of ref document: 20160805

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20160729

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20160801

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20160525

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2585555

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20161006

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E012346

Country of ref document: EE

Effective date: 20160725

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 21497

Country of ref document: SK

REG Reference to a national code

Ref country code: EE

Ref legal event code: HE1A

Ref document number: E012346

Country of ref document: EE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 6

REG Reference to a national code

Ref country code: NO

Ref legal event code: CHAD

Owner name: ZOETIS SERVICES LLC, US

REG Reference to a national code

Ref country code: HR

Ref legal event code: PNAN

Ref document number: P20160601

Country of ref document: HR

Owner name: ZOETIS SERVICES LLC, US

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602012018933

Country of ref document: DE

Representative=s name: KRAUS & WEISERT PATENTANWAELTE PARTGMBB, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 602012018933

Country of ref document: DE

Owner name: ZOETIS SERVICES LLC (N.D.GES.D.STAATES DELAWAR, US

Free format text: FORMER OWNER: ZOETIS SERVICES LLC, FLORHAM PARK, N.J., US

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20160401733

Country of ref document: GR

Effective date: 20161020

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160525

REG Reference to a national code

Ref country code: SI

Ref legal event code: SP73

Owner name: ZOETIS SERVICES LLC; US

Effective date: 20170111

Ref country code: DE

Ref legal event code: R097

Ref document number: 602012018933

Country of ref document: DE

Ref country code: HU

Ref legal event code: HC9C

Owner name: ZOETIS SERVICES LLC, US

Free format text: FORMER OWNER(S): ZOETIS SERVICES LLC, US

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E029810

Country of ref document: HU

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: SK

Ref legal event code: TE4A

Ref document number: E 21497

Country of ref document: SK

Owner name: ZOETIS SERVICES LLC, PARSIPPANY, NEW JERSEY, US

Effective date: 20170310

26N No opposition filed

Effective date: 20170228

REG Reference to a national code

Ref country code: FR

Ref legal event code: CA

Effective date: 20170725

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

REG Reference to a national code

Ref country code: CH

Ref legal event code: SPCF

Free format text: PRODUCT NAME: SAROLANER; REGISTRATION NO/DATE: SWISSMEDIC 66273 06.12.2017

Filing date: 20180227

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 802240

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160525

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20160601

Country of ref document: HR

Payment date: 20190129

Year of fee payment: 8

REG Reference to a national code

Ref country code: CH

Ref legal event code: SPCG

Free format text: PRODUCT NAME: SAROLANER; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66273 06.12.2017

Spc suppl protection certif: C02683723/01

Filing date: 20180227

Extension date: 20321205

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20160601

Country of ref document: HR

Payment date: 20200204

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160925

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20160601

Country of ref document: HR

Payment date: 20210209

Year of fee payment: 10

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20160601

Country of ref document: HR

Payment date: 20220210

Year of fee payment: 11

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20160601

Country of ref document: HR

Payment date: 20221229

Year of fee payment: 12

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230524

REG Reference to a national code

Ref country code: CH

Ref legal event code: SPCN

Spc suppl protection certif: C02683723/01

Representative=s name: E. BLUM AND CO. AG, CH

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20160601

Country of ref document: HR

Payment date: 20240124

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BG

Payment date: 20241227

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MT

Payment date: 20241227

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20250114

Year of fee payment: 14

Ref country code: LU

Payment date: 20250110

Year of fee payment: 14

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20160601

Country of ref document: HR

Payment date: 20250113

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HU

Payment date: 20250205

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20250129

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20250127

Year of fee payment: 14

Ref country code: DE

Payment date: 20250109

Year of fee payment: 14

Ref country code: HR

Payment date: 20250113

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20250206

Year of fee payment: 14

Ref country code: RO

Payment date: 20250120

Year of fee payment: 14

Ref country code: FI

Payment date: 20250128

Year of fee payment: 14

Ref country code: LT

Payment date: 20250117

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20250311

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20250210

Year of fee payment: 14

Ref country code: IE

Payment date: 20250127

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NO

Payment date: 20250127

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LV

Payment date: 20250109

Year of fee payment: 14

Ref country code: GR

Payment date: 20250127

Year of fee payment: 14

Ref country code: AT

Payment date: 20250127

Year of fee payment: 14

Ref country code: CH

Payment date: 20250301

Year of fee payment: 14

Ref country code: EE

Payment date: 20250113

Year of fee payment: 14

Ref country code: SI

Payment date: 20250113

Year of fee payment: 14

Ref country code: BE

Payment date: 20250113

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20250110

Year of fee payment: 14

Ref country code: FR

Payment date: 20250110

Year of fee payment: 14

Ref country code: CZ

Payment date: 20250114

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20250109

Year of fee payment: 14

Ref country code: IT

Payment date: 20250212

Year of fee payment: 14

Ref country code: GB

Payment date: 20250109

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RS

Payment date: 20250110

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20250121

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AL

Payment date: 20250204

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20250110

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MK

Payment date: 20250117

Year of fee payment: 14